4.7 Article

Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis An Expert Statement

期刊

EUROPEAN HEART JOURNAL
卷 39, 期 15, 页码 1224-1245

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehx211

关键词

closure devices; regurgitation; transcatheter

资金

  1. Medtronic
  2. St. Jude Medical
  3. Philips Healthcare
  4. Boston Scientific
  5. Edwards Lifesciences
  6. Sorin
  7. Neochord
  8. Artech
  9. Aptiva Medica
  10. Gada Group
  11. Philips
  12. Edwards
  13. Abbott
  14. LivaNova
  15. St. Jude
  16. Direct Flow
  17. Abbott Vascular
  18. AstraZeneca
  19. Biotronik
  20. Cardialysis
  21. GLG Research
  22. SinoMedical Sciences Technology
  23. Societe Europa Digital Publishing
  24. Stentys France
  25. Svelte Medical Systems
  26. Volcano
  27. Xeltis

向作者/读者索取更多资源

The VARC (Valve Academic Research Consortium) for transcatheter aortic valve replacement set the standard for selecting appropriate clinical endpoints reflecting safety and effectiveness of transcatheter devices, and defining single and composite clinical endpoints for clinical trials. No such standardization exists for circumferentially sutured surgical valve paravalvular leak (PVL) closure. This document seeks to provide core principles, appropriate clinical endpoints, and endpoint definitions to be used in clinical trials of PVL closure devices. The PVL Academic Research Consortium met to review evidence and make recommendations for assessment of disease severity, data collection, and updated endpoint definitions. A 5-class grading scheme to evaluate PVL was developed in concordance with VARC recommendations. Unresolved issues in the field are outlined. The current PVL Academic Research Consortium provides recommendations for assessment of disease severity, data collection, and endpoint definitions. Future research in the field is warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据